Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease

Yifei Zhang, Chunxiu Hu, Jie Hong, Jun Zeng, Shenghan Lai, Ankang Lv, Qing Su, Yan Dong, Zhiguang Zhou, Weili Tang, Jiajun Zhao, Lianqun Cui, Dajin Zou, Dawang Wang, Hong Li, Chao Liu, Guoting Wu, Jie Shen, Dalong Zhu, Weiqing Wang & 3 others Weifeng Shen, Guang Ning, Guowang Xu

Research output: Contribution to journalArticle

Abstract

RESEARCH DESIGN AND METHODS Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients in metformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration).

RESULTS A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species comparedwith glipizide, especially at the 2- And 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P <0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P <0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend inmetformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal.

CONCLUSIONS Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.

OBJECTIVE We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabetic patients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study.

Original languageEnglish (US)
Pages (from-to)2804-2812
Number of pages9
JournalDiabetes Care
Volume37
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Glipizide
Metformin
Therapeutic Uses
Type 2 Diabetes Mellitus
Coronary Artery Disease
Lipids
Serum
Triglycerides
Therapeutics
Liquid Chromatography
Mass Spectrometry
Carbon

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing
  • Medicine(all)

Cite this

Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease. / Zhang, Yifei; Hu, Chunxiu; Hong, Jie; Zeng, Jun; Lai, Shenghan; Lv, Ankang; Su, Qing; Dong, Yan; Zhou, Zhiguang; Tang, Weili; Zhao, Jiajun; Cui, Lianqun; Zou, Dajin; Wang, Dawang; Li, Hong; Liu, Chao; Wu, Guoting; Shen, Jie; Zhu, Dalong; Wang, Weiqing; Shen, Weifeng; Ning, Guang; Xu, Guowang.

In: Diabetes Care, Vol. 37, No. 10, 01.10.2014, p. 2804-2812.

Research output: Contribution to journalArticle

Zhang, Y, Hu, C, Hong, J, Zeng, J, Lai, S, Lv, A, Su, Q, Dong, Y, Zhou, Z, Tang, W, Zhao, J, Cui, L, Zou, D, Wang, D, Li, H, Liu, C, Wu, G, Shen, J, Zhu, D, Wang, W, Shen, W, Ning, G & Xu, G 2014, 'Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease', Diabetes Care, vol. 37, no. 10, pp. 2804-2812. https://doi.org/10.2337/dc14-0090
Zhang, Yifei ; Hu, Chunxiu ; Hong, Jie ; Zeng, Jun ; Lai, Shenghan ; Lv, Ankang ; Su, Qing ; Dong, Yan ; Zhou, Zhiguang ; Tang, Weili ; Zhao, Jiajun ; Cui, Lianqun ; Zou, Dajin ; Wang, Dawang ; Li, Hong ; Liu, Chao ; Wu, Guoting ; Shen, Jie ; Zhu, Dalong ; Wang, Weiqing ; Shen, Weifeng ; Ning, Guang ; Xu, Guowang. / Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease. In: Diabetes Care. 2014 ; Vol. 37, No. 10. pp. 2804-2812.
@article{81f912c9bfbe4358a29eecba4197ac66,
title = "Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease",
abstract = "RESEARCH DESIGN AND METHODS Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients in metformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration).RESULTS A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species comparedwith glipizide, especially at the 2- And 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P <0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P <0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend inmetformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal.CONCLUSIONS Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.OBJECTIVE We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabetic patients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study.",
author = "Yifei Zhang and Chunxiu Hu and Jie Hong and Jun Zeng and Shenghan Lai and Ankang Lv and Qing Su and Yan Dong and Zhiguang Zhou and Weili Tang and Jiajun Zhao and Lianqun Cui and Dajin Zou and Dawang Wang and Hong Li and Chao Liu and Guoting Wu and Jie Shen and Dalong Zhu and Weiqing Wang and Weifeng Shen and Guang Ning and Guowang Xu",
year = "2014",
month = "10",
day = "1",
doi = "10.2337/dc14-0090",
language = "English (US)",
volume = "37",
pages = "2804--2812",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease

AU - Zhang, Yifei

AU - Hu, Chunxiu

AU - Hong, Jie

AU - Zeng, Jun

AU - Lai, Shenghan

AU - Lv, Ankang

AU - Su, Qing

AU - Dong, Yan

AU - Zhou, Zhiguang

AU - Tang, Weili

AU - Zhao, Jiajun

AU - Cui, Lianqun

AU - Zou, Dajin

AU - Wang, Dawang

AU - Li, Hong

AU - Liu, Chao

AU - Wu, Guoting

AU - Shen, Jie

AU - Zhu, Dalong

AU - Wang, Weiqing

AU - Shen, Weifeng

AU - Ning, Guang

AU - Xu, Guowang

PY - 2014/10/1

Y1 - 2014/10/1

N2 - RESEARCH DESIGN AND METHODS Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients in metformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration).RESULTS A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species comparedwith glipizide, especially at the 2- And 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P <0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P <0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend inmetformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal.CONCLUSIONS Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.OBJECTIVE We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabetic patients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study.

AB - RESEARCH DESIGN AND METHODS Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients in metformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration).RESULTS A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species comparedwith glipizide, especially at the 2- And 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P <0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P <0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend inmetformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal.CONCLUSIONS Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.OBJECTIVE We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabetic patients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study.

UR - http://www.scopus.com/inward/record.url?scp=84908215156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908215156&partnerID=8YFLogxK

U2 - 10.2337/dc14-0090

DO - 10.2337/dc14-0090

M3 - Article

VL - 37

SP - 2804

EP - 2812

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -